|Last Price$41.82||Day Change (%)0.98%|
|Open Price$41.34||Day Change ($)0.40|
|Day Range40.05–42.00||52-Week Range37.59–76.68|
As of Fri 2/12/2016 5:00:00 PM | USD
Correction: Fitch Affirms Mylan at 'BBB-' on Meda Acquisition Announcement; Outlook Stable
Statement by the Board of Directors of Meda in relation to the public offer by Mylan
Mylan Reaches $7.2 Billion Deal For Sweden's Meda
Watson Pharmaceuticals WPI scored big Tuesday when the Food and Drug Administration approved the firm's generic fentanyl patch. We may modestly increase our fair value estimate for Watson and will maintain our fair value estimate for competitor Mylan Laboratories MYL . The pain patch is one of the ...
Mylan Laboratories MYL reported impressive second-quarter results Wednesday. However, most of the improvement was temporary and will not affect our fair value estimate. The quarter was only slightly better than we expected after excluding a one-time litigation payment and proceeds from a product ...
UPDATE: European stocks slammed to lowest since 2013 as fear selling returns
These mutual funds have far more than their recent success going for them.
Plus, a top executive bolts from eBay, Brazilian telcos get cheap, and more.
Drug Delivery Market Analysis - Forecast (2015-2020) - Prominent Players are 3M, Abbott Laboratories, Thermo Fischer Scientific, Medtronics, Roche & Baxter - Research and Markets
Goldman Makes Debt Financing A Priority